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ABSTRACT
Post-marketing drug withdrawals can be associated
with various events, ranging from safety issues such
as reported deaths or severe side-effects, to a mul-
titude of non-safety problems including lack of effi-
cacy, manufacturing, regulatory or business issues.
During the last century, the majority of drugs vol-
untarily withdrawn from the market or prohibited by
regulatory agencies was reported to be related to
adverse drug reactions. Understanding the under-
lying mechanisms of toxicity is of utmost impor-
tance for current and future drug discovery. Here,
we present WITHDRAWN, a resource for withdrawn
and discontinued drugs publicly accessible at http://
cheminfo.charite.de/withdrawn. Today, the database
comprises 578 withdrawn or discontinued drugs,
their structures, important physico-chemical prop-
erties, protein targets and relevant signaling path-
ways. A special focus of the database lies on the
drugs withdrawn due to adverse reactions and toxic
effects. For approximately one half of the drugs in the
database, safety issues were identified as the main
reason for withdrawal. Withdrawal reasons were ex-
tracted from the literature and manually classified
into toxicity types representing adverse effects on
different organs. A special feature of the database is
the presence of multiple search options which will
allow systematic analyses of withdrawn drugs and
their mechanisms of toxicity.
INTRODUCTION
Efficacy and safety are two decisive factors that affect the
viability of a chemical entity while furthering in the drug
discovery pipeline. Consequently, the financial burden on
pharmaceutical companies grows higher when the chemical
entities tend to fail in late stages of clinical trials (1). How-
ever, a significant number of new chemical entities (NCEs)
were recalled from the market post to their regulatory ap-
proval due to various reasons ranging from inefficiency to
severe side-effects to financial and regulatory concerns. Ad-
verse drug reactions (ADRs) not only account for market
withdrawals but also for changes in labels or introduction of
new black-box warnings for prescription drugs (2). ADRs
can be interpreted either as primary effects elicited after
modulation of the therapeutic (or primary) target or unin-
tended effects due to interactions with off-targets. In few in-
stances, the primary target is expressed in multiple organs
and simultaneously targeted, leading to the therapeutic ef-
fect in the target tissue and unwanted effects in other tissues.
A well-known class of drugs that cause adverse reactions
due to their activity at primary target are antiarrhythmic
drugs, the benefits of which are, in few cases, hindered due
to aggravation of arrhythmia which is the indication be-
ing treated (3). This effect is due to modulation of the al-
pha subunit of a potassium ion channel (human Ether-a`-
go-go-related gene, hERG), which is primarily associated
with regulation of cardiac action potentials (4). The hERG
channel is also a prominent off-target example whose un-
intended modulation can cause severe side-effects. This has
ultimately lead tomarket withdrawal of drugs inhibiting the
hERG channel, a classical example being the withdrawal of
the antihistaminic drug terfenadine due to severe arrhyth-
mias and death (5).
Although there is much progress in elucidation and un-
derstanding of themechanisms leading to drug related toxic
effects, gaining clearer insights about these effects at cel-
lular and biochemical level is much needed to appropri-
ately adjust or reinvent the development strategies so as to
overcome the attrition during clinical trial phases of drug
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discovery and withdrawal after drug approval (6–8). This
toxicological knowledge could be used to develop a panel
of relevant in vitro assays that could mechanistically exam-
ine the effects and profile the propensity of drugs to cause
ADRs (9). In contrast to the majority of ADR cases which
are relatively frequent andmostly dose-dependent, few side-
effects are idiosyncratic drug reactions (IADRs), i.e. the ex-
tremely rare drug reactions which occur unpredictably in a
population. The target organs that are most commonly as-
sociated with idiosyncratic events include liver, cardiovas-
cular and central nervous systems (10–12). Hepatocellular
and cholestatic drug-induced liver injury (DILI), liver fail-
ure and hepatic necrosis are the common patterns of IADRs
associatedwith the liver. Limited knowledge exists to under-
stand the underlyingmechanisms of such IADRs. However,
it is apparent that IADRs develop via complex mechanisms
which are subjective to both differential patient responses
and drug combination effects that result from simultane-
ous triggering of multiple off-targets (13). Factors associ-
ated with differential patient responses include genetic at-
tributes like single nucleotide polymorphisms (SNPs) and
mutations, and non-genetic attributes such as gender, age
and co-treatments (14). Drug-induced events are a result of
various effects ranging from direct activity on organs (e.g.
on cardiovascular systems) to reactivity of active metabo-
lites of drugs to interactions with biological transporters
(15).
Over the decades, drug regulatory agencies, pharmaceu-
tical companies and various clinical studies have reported
the events of drug withdrawals due to side-effects (16–
18). About 2.3 million adverse event reports were collected
against∼6000 marketed drugs between 1969 and 2002 (19).
Yet, only a small proportion (75 drugs; ∼1%) of these mar-
keted drugs were withdrawn during this period. Another
study reported that∼95 drugs were documented to be with-
drawn due to death as the primary reason between 1950 and
2013 (17). However, not all of these drugs were withdrawn
world-wide. Most drugs were reported to be withdrawn in
the Unites States and European countries.
Several public resources contain information relevant to
drug withdrawals (e.g. websites from regulatory agencies,
World Health Organization’s consolidated list for with-
drawn drugs and scientific literature). However, in many
cases, the information is hidden in regulatory documents
and not easily accessible, impeding comprehensive analy-
ses. Furthermore, there exists no single resource reporting a
complete list of drugs withdrawn due to safety concerns. In
order to allow access to a variety of information related to
drug withdrawals as well as shed light on the mechanisms
of ADRs, we here present WITHDRAWN––a resource for
withdrawn and discontinued drugs. We collected a list of
more than 500 drugs/drug products, which were withdrawn
or discontinued in at least one country, and assembled in-
formation regarding their molecular targets, pathways and
toxicities. For approximately half of the drugs, extensive lit-
erature search revealed that toxic events are associated with
thewithdrawal. Thus,WITHDRAWNcan be seen as a plat-
form to understand the mechanisms for severe ADRs due
to primary and off-target interactions of drugs, simultane-
ous perturbation of complex biological pathways and ge-
netic polymorphisms (SNPs). Furthermore, it providesmul-
tiple search options to systematically analyse molecules of
interest by performing different types of molecular similar-
ity search across the database’s drugs and can be a valuable
resource for scientists in the drug development and toxicity
prediction field.
MATERIALS AND METHODS
Withdrawn and discontinued drugs
A number of resources including the drug collections from
the U.S. Food and Drug Administration (FDA; http://
www.fda.gov/), the European Medicines Agency (EMA;
http://www.ema.europa.eu/ema/), peer-reviewed literature
(17), public databases such as DrugBank (20), e-Drug3D
(21) and text-books (16) were searched in order to ex-
tract information on drug withdrawals. Monoclonal an-
tibodies and substance combinations were removed from
the dataset. Currently, the database comprises two sets
of drugs: withdrawn and discontinued. A total of 270
drugs, that were identified to be withdrawn or recalled in
at least one country/market due to safety issues are in-
cluded in the former set while the latter consists of 308
drugs that were suspended or discontinued in at least one
market due to unclear reasons. The chemical structures of
the withdrawn/discontinued drugs were standardized us-
ing the JChem Suite (Instant JChem version 14.10.27.0,
ChemAxon (http://www.chemaxon.com)). The standard-
ization steps included aromatization of the structures, ad-
dition of explicit hydrogens, removal of salts, and genera-
tion of 3D structures. InChIKeys were calculated for the
standardized structures and used to join structures from
different datasets and to remove duplicates. In addition to
InChIKeys, the set was scanned for duplicates using chem-
ical names, canonical smiles and external identifiers.
In many cases, the reason(s) for withdrawal and as-
sociated toxicity was directly provided by the source.
The reasons were manually extracted for the remaining
drugs by performing literature search. Furthermore, the
years of first approval, first and last withdrawal, and the
year of first reported death for all the withdrawn drugs
and most of the discontinued drugs were extracted from
the literature. Additionally, the Anatomical Therapeutic
Chemical (ATC) codes and external chemical identifiers
were collected to link the drugs to the public databases
WHO ATC index (http://www.whocc.no/atc ddd index/),
ChEMBL (22) and PubChem (23), respectively. Exter-
nal identifiers were extracted using the PubChem Identi-
fier Exchange Service (https://pubchem.ncbi.nlm.nih.gov/
idexchange/idexchange.cgi) whereas the ATC codes were
collected by looking for drug names in the WHO ATC in-
dex. For those drugs without an ATC code assigned by
the WHO, pseudo-ATC class names were assigned based
on their primary indication areas. The acute oral toxicity
class was calculated for each drug using the ProTox web-
server (24). The toxicity classes (ranging from 1 to 6) are
based on the Globally Harmonized System of Classifica-
tion and Labelling of Chemicals (GHS; https://www.osha.
gov/dsg/hazcom/ghs.html) which classifies compounds us-
ing their median lethal doses (LD50). Drugs that demon-
strated very low structural similarity to the ProTox dataset
were assigned to the class 0.
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Protein targets
Human protein targets for withdrawn and discontinued
drugswere obtained from theComparative Toxicogenomics
Database (CTD) (25) and the ChEMBL database v. 19 (22).
The targets from CTD were filtered to obtain only interac-
tions with the interaction types involving activity, binding,
transport or metabolic processing. The ChEMBL targets
were filtered using the following criteria, adapted from the
recommendations on search criteria by Bajorath et al. (26).
First, all interactions with an activity comment ‘inactive’,
‘inconclusive’ or ‘not active’ were removed. Second, only in-
teractions with nanomolar (nM) standard units were kept.
Third, all interactions with a confidence score below 4 were
deleted to remove all non-protein targets. Fourth, only in-
teractions with standard activity relations ‘ = ’, ‘<’, ‘<<’,
‘< = ’, ‘ = = ’ and those without a standard activity rela-
tion were kept. In the last step, all interactions marked with
target types as cell-line and ADMET were omitted to re-
tain only interactions those with protein targets measured
in functional or binding assays. As a result, we retained a
total of 1.4 million compound-target interactions. Target
interactions were assigned to the withdrawn/discontinued
drugs by mapping the ChEMBL/CTD compound identi-
fiers which resulted in a total of 20,558 drug-target inter-
actions. These involved 327 drugs and 946 distinct human
protein targets. To provide additional information concern-
ing adverse effects, drug-target interactions were classified
into therapeutic and potential off-targets. Therapeutic or
primary drug targets were identified using mechanism of
action information from ChEMBL (22), primary target in-
formation from PDB (27), pharmacological action from
Drugbank (20) as well as the Therapeutic Target Database
TTD (28). Information regarding targets considered as off-
targets was gathered from the Novartis Safety Panel list
published by Lounkine et al. (29).
Enriched pathways
In order to emphasise the interpretation of drug-target in-
teractions at molecular level, we enriched the biological
pathways from ConsensusPathDB (30) using the human
protein targets from our database. A total of 149 KEGG
pathways were enriched with an enrichment P-value> 0.01
while ensuring that at least two protein targets are involved
in each pathway. The 149 enriched pathways comprise dif-
ferent signaling, metabolic and biochemical pathways in ad-
dition to the drug-target interaction pathways. Altogether,
703 human protein targets were found to be involved in the
enriched pathways.
Genetic variations
Information on genetic variations, or widely known as sin-
gle nucleotide polymorphisms (SNPs), were extracted from
the dbSNP database (31). To extract the SNP informa-
tion from dbSNP for the human protein targets within our
database, the BioMart R package (32) was used. The hu-
man genome assembly GRCh38.p3, provided by the En-
sembl database (33), was used as a reference genome. SNP
information extraction started with a collection of gene
symbols or names as defined by the HUGO Gene Nomen-
clature Committee (HGNC) database (34). The Ensembl-
Mart was queried for HGNC symbols and the correspond-
ing Ensembl transcript identifiers were extracted for each
gene. The chromosomal position was identified for each
transcript and SNP identifiers were used to get additional
information including minor allele frequency (MAF) and
function predictions from SNP-Mart. This information was
mapped to the genes queried for on Ensemble-Mart using
the SNP identifiers and transcript identifiers. In order to
identify the most important variations, only those SNPs lo-
cated within the coding region of a protein and marked as
missense variants with an MAF value were retained. A to-
tal of 889 human protein targets were identified to be as-
sociated with 27 790 unique SNP identifiers. In total, 1731
SNPs have a MAF >1%.
Toxicity types
A total of 14 categories of toxicity types were defined based
on the adverse effects associated with drug withdrawal.
These include the following toxicity types: hepatic, car-
diovascular, haematological, dermatological, carcinogenic,
neurological, renal, gastrointestinal, ophthalmic, muscular,
reproductive and respiratory toxicity as well as the type
‘multiple toxicities’ comprising compounds with observed
multiple organ failure as well as ‘unknown toxicity’ where
no specific toxic effect could be identified, although a safety
issue was associated with the withdrawal. The toxicity types
were manually assigned based on the reasons available and
also the reasons extracted from the literature. The number
of withdrawn/discontinued drugs associated with each tox-
icity type is summarized in Figure 1 and Supplementary Ta-
ble S1.
Server, database and system requirements
WITHDRAWN is based on a relational MySQL database
(http://www.mysql.com/). All data is stored on the MySQL
database and WITHDRAWN is hosted as a Java web
application on a Linux virtual server, accessible at http:
//cheminfo.charite.de/withdrawn. We strongly recommend
using a latest Mozilla Firefox, Google Chrome or Safari
browser, with JavaScript options enabled, to access the web-
site.
DATABASE SEARCH OPTIONS
The data presented by WITHDRAWN can be queried via
multiple search forms, as summarized in Figure 2. A quick
and simple way is to browse through the lists of withdrawn
and discontinued drugs. Different search options available
on the database include.
Drug search
Drugs can be searched using multiple options. In case a di-
rectmatch by name or synonym is not possible, the structure
of the queried name is obtained from PubChem and five
most similar withdrawn/discontinued drugs will be identi-
fied and displayed to the users. When providing a structure
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Figure 1. Overview of toxicity types associated with drug withdrawals.
input via the molecule sketching tool, the user has the flexi-
bility to search for database compounds at different levels of
Tanimoto similarity (fingerprint similarity using MACCS
keys) and also to adjust the number of results to be dis-
played. In addition, a sub-structure search, usingUllmann’s
algorithm for subgraph isomerism (35), was implemented
to provide an option to lookup for withdrawn/discontinued
drugs that contain the query structure. Additionally, drugs
can be searched using ATC codes. A detailed drug record
displays information about drug withdrawal, physicochem-
ical properties and links to external databases. The users can
also view the target interactions of the selected drug. Two
separate tables for ChEMBL and CTD interactions are dis-
played. ChEMBL interactions can additionally be filtered
using different activity value cutoffs.
Target search
The users can search for protein targets by providing a gene
name, UniProt entry number or UniProt entry name (36)
as query in the target search form. In addition, it is pos-
sible to browse protein targets using their ChEMBL clas-
sification. The resulting target record displays various pro-
tein identifiers, PDB (http://www.rcsb.org) structures, and
links to external target databases. In addition, the interac-
tions of the target with withdrawn/discontinues drugs can
be viewed in the same page. The information includes ac-
tivity types, units and values as well as the organism and
information source. Furthermore, the information on bio-
logical pathways and SNPs, including amino acid changes,
peptide positions, MAFs, PolyPhen scores (37) and links to
dbSNP, were added in the detailed record of a target.
Pathway search
To provide clear insights on withdrawn drug-target inter-
action effects, the pathway maps were extracted from the
KEGGdatabase (38,39) for all the enriched biological path-
ways. In every pathway map, the targets that have an in-
teraction with withdrawn drugs are highlighted. Pathways
can be accessed via a selection list. Additionally, the targets
highlighted within themap are listed below to provide a link
to interacting drugs.
Toxicity type search
Alternatively, the drugs can be browsed by toxicity type. An
interactive wheel was designed to visualize different toxic-
ity types using the open source D3 visualization libraries
(http://d3js.org/). The users can see number of drugs in each
toxicity type as well as the distribution of the drugs into dif-
ferent ATC classes within each toxicity type. Furthermore,
the list of drugs classified in each toxicity type can be exclu-
sively viewed by clicking on the toxicity type. Major with-
drawal reasons under each toxicity type are summarized in
Figure 1 and Supplementary Table S1.
USE CASE
The following use case, represented in Figure 3, illustrates
the utility of WITHDRAWN as a knowledge-base to un-
derstand the mechanism of adverse drug reactions associ-
ated with drug withdrawals:
A search for the drug sibutramine, originally developed
by Knoll Pharmaceuticals, as an appetite suppressant for
treatment of exogenous obesity reveals that it was recalled
in the USA in 2010 due to adverse cardiovascular events
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Figure 2. Schematic representation ofWITHDRAWN: various search options and different entity types: drugs, targets, pathways, toxicity types and SNPs.
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Figure 3. Case study––use of WITHDRAWN in connecting links between drugs, targets and SNPs in toxicological context.
including myocardial infarctions and stroke (40). Sibu-
tramine is a non-selective inhibitor that acts by inhibit-
ing the reuptake of the three monoamine neurotransmit-
ters: serotonin, dopamine and norepinephrine. By searching
for sibutramine targets in WITHDRAWN, the drug record
shows additional drug-target interactions including the cy-
tochromes CYP2B6, CYP2C19 and CYP2D6 as well as
the 2B-adrenergic receptor (ADRA2B) where sibutramine
exhibits similar activity as at the primary targets. WITH-
DRAWN shows four genetic variants for CYP2B6 with
a MAF above 1% (rs3745274, rs3211371, rs8192709 and
rs28399499). Indeed, it has been shown that CYP2B6 vari-
ations, particularly rs3745274, may lead to a significant in-
crease in the blood concentration of sibutramine and its ac-
tive metabolites (41,42). As summarized by Zhang et al.
(43), the increased drug concentration could result in an
increased off-target activity at ADRA2B which, through
an increased norepinephrine release, can lead to increased
blood pressure and adverse cardiovascular events. The ex-
ample emphasizes the importance of considering extensive
drug-target and pharmacogenetics studies during drug de-
velopment.
CONCLUSIONS
WITHDRAWN is a rich resource of withdrawn or discon-
tinued drugs. Due to a relatively small number of drugs
withdrawn per year (∼10), we will update the database an-
nually to ensure good coverage and high standard. The
database not only contains information related to drug
withdrawals and associated adverse drug reactions but also
drug-target interactions and genetic variations of the pro-
tein targets. The drug-target interaction information is
mapped to biological context by enriching the relevant
pathways. The illustrated case study proves that, connecting
links between drugs, targets and SNPs may explain the un-
derlying mechanisms of toxicity. The knowledge presented
in the database can improve the insights of drug-target in-
teractions in toxicological context and provide the rationale
for further off-target profiling and enhanced pharmacoge-
netics studies in different populations.
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